Skip to main content

Table 2 Maternal and neonatal outcomes according to the two screening strategies

From: Change in prevalence of gestational diabetes and obstetric complications when applying IADPSG screening criteria in a Belgian French speaking University Hospital. A retrospective cohort study

 

Group A

Group B

OR (95%CI)

p-value

aOR (95% CI)a

Gestational Diabetes Mellitus

n = 3496

n = 2555

   

119 (3.4%)

416 (16.28%)

5.51 (4.46–6.81)

< 0.001

5.53 (4.48–6.84)

Primary Cesarean section

n = 3135

n = 2321

   

386 (12.31%)

320 (13.79%)

1.13 (0.97–1.33)

0.109

1.07 (0.91–1.26)

Gestational hypertensive disorders

n = 3496

n = 2555

   

101 (2.89%)

73 (2.86%)

0.98 (0 .72–1.34)

0.942

0.93 (0.69–1.27)

Preterm birth

n = 3496

n = 2555

   

228 (6.52%)

162 (6.43%)

0.97 (0.78–1.19)

0.777

0.97 (0 .79–1.2)

5′ Apgar score < 7

n = 3489

n = 2547

   

76 (2.18%)

56 (2.2%)

1.009 (0.71–1.43)

0.957

0.98 (0.69–1.40)

Transfer to NICU

n = 3404

n = 2547

   

277 (8.14%)

208 (8.17%)

1.003 (0.83–1.21)

0.968

0.97 (0.81–1.18)

Neonatal hypoglycaemia

n = 392

n = 438

   

65 (16.58%)

90 (20.55%)

1.3 (0.91–1.85)

0.144

1.37 (0.96–1.97)

Shoulder dystocia

n = 3489

n = 2547

   

64 (1.83%)

56 (2.20%)

1.2 (0.83–1.72)

0.317

1.19 (0.83–1.72)

LGA

n = 3496

n = 2555

   

433 (12.39%)

276 (10.81%)

0.85 (0.73–1.006)

0.059

0.87 (0.74–1.03)

Macrosomia

n = 3496

n = 2555

   

319 (9.12%)

198 (7.75%)

0.83 (0 .69–1.006)

0.059

0.85 (0.71–1.03)

  1. aadjusted for nationality and parity